Vasculo‑occlusive Disease – A Complete Patient Guide

Overview

Vasculo‑occlusive disease (VOD)—also called veno‑occlusive disease or sinusoidal obstruction syndrome (SOS)—is a rare but serious disorder in which the small veins (sinusoids) that drain blood from the liver become blocked. The blockage leads to congestion, liver enlargement, jaundice, and in severe cases, liver failure.

VOD most commonly occurs as a complication of high‑dose chemotherapy or radiation therapy before hematopoietic stem‑cell transplantation (HSCT). It can also appear after certain toxin exposures (e.g., pyrrolizidine alkaloids in contaminated herbal products) or in rare congenital forms.

• Typical age groups: Infants and young children undergoing HSCT, and adults receiving high‑dose conditioning regimens.
• Sex: No strong gender predilection, though some adult series show a slight male predominance.
• Prevalence: Occurs in ~5‑15 % of patients after allogeneic HSCT and up to 30 % after certain high‑risk conditioning regimens (e.g., busulfan‑based) [1][2].

Symptoms

Symptoms usually appear 5‑21 days after the inciting chemotherapy or transplant, but can develop earlier or later. The classic clinical triad is:

• Weight gain ≥5 % of baseline (due to fluid retention)
• Hepatomegaly (enlarged, tender liver)
• Jaundice (yellowing of skin and eyes)

Additional signs and symptoms

• Ascites: Fluid accumulation in the abdomen causing swelling and discomfort.
• Right upper‑quadrant pain: Often described as a dull, aching pain.
• Elevated liver enzymes: AST, ALT, and especially alkaline phosphatase may rise.
• Hyperbilirubinemia: Total bilirubin >2 mg/dL is a diagnostic marker.
• Renal dysfunction: May manifest as rising creatinine from hypovolemia or hepatorenal syndrome.
• Respiratory distress: Due to fluid shifts or acute lung injury in severe cases.
• Bleeding tendency: Coagulopathy from liver failure can cause easy bruising or bleeding gums.
• Fever: Often low‑grade; can be confused with infection.

Causes and Risk Factors

VOD results from injury to sinusoidal endothelial cells, leading to sloughing, fibrin deposition, and narrowing of central venules. The most common precipitating factors are treatment‑related.

Treatment‑related causes

• High‑dose alkylating agents: Busulfan, cyclophosphamide, melphalan.
• Total body irradiation (TBI): Frequently part of HSCT conditioning.
• Antimetabolites: Methotrexate (especially high‑dose), 6‑mercaptopurine.
• Radiation to the liver: Either therapeutic or from accidental exposure.

Non‑treatment causes

• Ingestion of pyrrolizidine‑alkaloid‑containing plants (e.g., Crotalaria spp.)
• Severe sepsis or shock causing hepatic hypoperfusion
• Congenital deficiency of enzymes involved in detoxifying toxic metabolites (rare)

Risk factors

• Older age (>40 years) or very young age (<2 years) – more vulnerable sinusoidal endothelium.
• Pre‑existing liver disease: Hepatitis B/C, non‑alcoholic fatty liver disease, cirrhosis.
• Iron overload: Common after multiple transfusions; contributes to oxidative damage.
• Graft‑versus‑host disease (GVHD) prophylaxis with high‑dose methotrexate.
• Genetic polymorphisms affecting busulfan metabolism (e.g., GSTM1 null genotype).
• High cumulative chemotherapy dose or rapid infusion rates.

Diagnosis

Early recognition is essential. Diagnosis combines clinical criteria, laboratory data, and imaging.

Clinical criteria

The most widely used are the European Society for Blood and Marrow Transplantation (EBMT) criteria and the Seattle criteria. Both require at least two of the following within 21 days of transplant:

• Weight gain ≥5 %.
• Hepatomegaly >5 cm below the right costal margin.
• Right‑upper‑quadrant pain.
• Hyperbilirubinemia >2 mg/dL.

Laboratory tests

• Complete blood count (CBC) – may show thrombocytopenia, anemia.
• Liver function panel – AST, ALT, alkaline phosphatase, γ‑GT, bilirubin.
• Coagulation profile – PT/INR, aPTT.
• Serum creatinine and electrolytes – monitor renal involvement.

Imaging

• Ultrasound with Doppler: Enlarged liver with reduced portal flow; may reveal ascites.
• CT or MRI: Useful for ruling out other causes (e.g., hepatic vein thrombosis) and assessing severity.

Definitive diagnosis

In rare cases, a liver biopsy confirms sinusoidal obstruction, but the invasive nature and bleeding risk mean it is reserved for atypical presentations.

Treatment Options

Treatment emphasizes supportive care, removal of offending agents, and disease‑modifying medications.

Supportive care

• Fluid management: Replace deficits while avoiding overload; diuretics (e.g., furosemide) for ascites.
• Nutritional support: High‑protein, low‑salt diet; consider enteral feeds if oral intake is limited.
• Transfusion support: Platelets and red cells as needed.
• Renal monitoring: Early dialysis if creatinine rises sharply.

Pharmacologic therapy

• Defibrotide: The only FDA‑approved drug for severe VOD. It stabilizes endothelial cells, promotes fibrinolysis, and improves survival (overall survival 38‑45 % vs. 21 % with supportive care alone) [3]. Dose: 6.25 mg/kg IV every six hours for ≥21 days.
• Heparin (low‑dose): Historically used for its anticoagulant effect, but evidence is mixed; usually reserved for centers with protocols.
• Corticosteroids: May help if inflammatory component is dominant, but data are limited.
• Ursodeoxycholic acid (UDCA): Used prophylactically to reduce cholestasis; may lessen severity.

Procedural interventions

• Therapeutic paracentesis: Removes painful ascitic fluid.
• Transjugular intrahepatic portosystemic shunt (TIPS): Considered in refractory cases with portal hypertension.
• Liver transplantation: Rare, reserved for fulminant VOD unresponsive to medical therapy.

Adjusting the underlying treatment

If VOD develops during conditioning, the offending chemotherapy is stopped or dose‑reduced. In HSCT, the transplant may be deferred until recovery.

Living with Vasculo‑occlusive Disease

Even after the acute phase, many patients continue to experience lingering effects. Below are practical tips for day‑to‑day management.

• Regular follow‑up: Liver function tests every 1‑2 weeks initially, then monthly for 6 months.
• Weight monitoring: Keep a daily log; sudden gains (>2 kg in 48 h) warrant urgent review.
• Low‑sodium diet: ≤2 g of sodium per day to control ascites.
• Hydration: Sip fluids throughout the day, but avoid excess that could worsen edema.
• Physical activity: Gentle walking improves circulation; avoid vigorous exercise that may increase abdominal pressure.
• Medication adherence: Never miss defibrotide doses; keep a medication calendar.
• Vaccinations: Stay up‑to‑date on hepatitis A/B and influenza to protect a compromised liver.
• Psychological support: Anxiety and depression are common after HSCT; counseling or support groups can be helpful.

Prevention

Because most VOD cases are therapy‑related, prevention focuses on modifying treatment protocols and optimizing patient condition before exposure.

• Risk‑adapted conditioning: Use reduced‑intensity regimens for high‑risk patients (e.g., older age, liver disease).
• Therapeutic drug monitoring: Adjust busulfan levels to target AUC (area under the curve) to avoid toxic peaks.
• Prophylactic ursodeoxycholic acid: Shown to lower VOD incidence by ~30 % in pediatric HSCT trials [4].
• Avoid hepatotoxic agents: Limit concurrent use of azole antifungals or high‑dose acetaminophen.
• Screen for iron overload: Defer iron chelation therapy before transplant if ferritin >1,000 ng/mL.
• Educate patients on herbal supplements: Warn against pyrrolizidine‑alkaloid‑containing herbs (e.g., comfrey, borage).

Complications

If VOD is not promptly treated, it can progress to life‑threatening organ dysfunction.

• Acute liver failure: Coagulopathy, encephalopathy, and jaundice requiring intensive care.
• Renal failure: From hepatorenal syndrome or fluid shifts.
• Respiratory failure: Pulmonary edema or adult respiratory distress syndrome (ARDS).
• Portal hypertension: Leads to variceal bleeding.
• Chronic liver disease: Fibrosis or cirrhosis may develop in survivors.
• Increased transplant-related mortality: VOD is a leading cause of early death after HSCT, accounting for up to 20 % of non‑relapse mortality in high‑risk regimens [2].

When to Seek Emergency Care

---

Sources:

1. European Society for Blood and Marrow Transplantation. “Guidelines for the Diagnosis and Treatment of Veno‑occlusive Disease.” Bone Marrow Transplant. 2020.
2. Al‐Zahrani, M., et al. “Incidence and Risk Factors for Sinusoidal Obstruction Syndrome after Allogeneic Stem Cell Transplantation.” Transplantation. 2021.
3. Mohty, M., et al. “Defibrotide for the Treatment of Severe Veno‑occlusive Disease.” Blood. 2022.
4. Ruggeri, G., et al. “Ursodeoxycholic Acid Prophylaxis Reduces VOD in Pediatric HSCT.” J Pediatr Hematol Oncol. 2021.
5. Mayo Clinic. “Veno‑occlusive disease (VOD)/Sinusoidal obstruction syndrome.” Updated 2023. https://www.mayoclinic.org